Marc Goodman
Stock Analyst at Leerink Partners
(2.90)
# 1,447
Out of 4,814 analysts
95
Total ratings
54.93%
Success rate
26.74%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $103.02 | +45.60% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.32 | +215.56% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $20.60 | +191.26% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $24.27 | +31.85% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $4.26 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $54.30 | -53.96% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $13.16 | +279.94% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $10.37 | +92.86% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $100.68 | +14.22% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $116.58 | +165.91% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $7.96 | +50.85% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $34.64 | +32.79% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $14.40 | +45.88% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $100.34 | +109.29% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $7.45 | +437.27% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.48 | +575.68% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $27.01 | -0.04% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $2.24 | +569.64% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $365.67 | -26.16% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $170.16 | -43.58% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.94 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $77.85 | -13.94% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $24.38 | +301.97% | 7 | Oct 5, 2017 |
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $103.02
Upside: +45.60%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.32
Upside: +215.56%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $20.60
Upside: +191.26%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $24.27
Upside: +31.85%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.26
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $54.30
Upside: -53.96%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $13.16
Upside: +279.94%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $10.37
Upside: +92.86%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $100.68
Upside: +14.22%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $116.58
Upside: +165.91%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $7.96
Upside: +50.85%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $34.64
Upside: +32.79%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $14.40
Upside: +45.88%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $100.34
Upside: +109.29%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $7.45
Upside: +437.27%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.48
Upside: +575.68%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $27.01
Upside: -0.04%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $2.24
Upside: +569.64%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $365.67
Upside: -26.16%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $170.16
Upside: -43.58%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $48.94
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $77.85
Upside: -13.94%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $24.38
Upside: +301.97%